ApprovedFDA approval

Utebzi (tebipenem pivoxil)

GlaxoSmithKline (GSK)

Marketer take

The first oral carbapenem in the US, for cUTI patients with limited oral options, which opens a discharge and outpatient message, tempered by antibiotic stewardship controls.

Sponsor company
GlaxoSmithKline (GSK)
Indication
To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options
Therapeutic area
Infectious disease
Event
FDA approval
Date
Jun 17, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move